Management of Stage III NSCLC Rapid Recommendation Update

Management of Stage III NSCLC Rapid Recommend...

Suivant

Breast Cancer Follow-Up and Surveillance After Primary Treatment Guideline Update

Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on ...  Afficher plus

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resist ...  Afficher plus

Épisodes Recommandés

Optimizing Novel Therapies and Surgery in Early-Stage NSCLC
ASCO Daily News

Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for patients and the role of surgery in the era of targ ...

  Afficher plus

ASCO24: Transforming the Lung Cancer Treatment Landscape
ASCO Daily News

<span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. Vamsi Velcheti and Nathan Pennell discuss novel approaches and key studies in lung cancer that were showcased at the 2024 ASCO Annu ...

  Afficher plus

ASCO24: The Era of the ADCs in NSCLC
ASCO Daily News

Drs. Vamsi Velcheti and Nathan Pennell discuss key lung cancer abstracts from the 2024 ASCO Annual Meeting, including data from LUMINOSITY and ADAURA, novel therapies in KRASG12C-mutant advanced NSCLC, and the need for effective adjuvant therapies for patients with rare mutati ...

  Afficher plus

Key Abstracts in GU Cancers at ASCO24
ASCO Daily News

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting.

<span style= "text-decoration: underline;">TRANSCRIPT</span>

  Afficher plus